In the experiment, a team at Harvard University embedded healthy stem cells from mouse embryos into the brains of adult laboratory rodents who were unable to use leptin. After the transplant the rodents were able to process leptin again.

Jeffery Macklis at Harvard University said “We’ve used complex circuitry as a test case for whether precisely selected and controlled neuron transplants could rewire the brain. What we found is these neurons not only turned into the right types of cells, but they sent signals to the recipient’s brain and received signals from the recipient’s brain. The next step for us is to ask parallel questions of other parts of the brain and spinal cord, those involved in ALS (motor neuron disease) and with spinal cord injuries.”

There are also many family banks across the country at large that privately bank cord blood units. Currently, there is no public donation option available in Canada, so parents who wish to store their children’s cord blood must do so privately.

However, the government has launched a new initiative that will see the establishment of a national public cord blood bank. Over the next 8 years, $42 million will be spending on the construction and establishment of a cord blood bank to which parents can donate their children’s umbilical cord blood. Over the next two years, a facility will be built in Ottawa – followed by facilities in Vancouver, Toronto and Edmonton.

In the meantime, parents can bank their children’s cord blood at private banks across the country. Cord blood banks in Insception offer parents affordable payment plans, in order to make the decision of whether or not to bank their children’s cord blood much easier.

Nerve fibers had also begun growing in the engineered teeth which indicates a near perfect transplant. Human transplants might become the standard in dental repair in the next decades.

The panel reversed an opinion issued last August by U.S. District Judge Royce Lamberth, who said the research likely violates the law against federal funding of embryo destruction.

The White House said the ruling was a victory for scientists and patients. “Responsible stem cell research has the potential to treat some of our most devastating diseases and conditions and offers hope to families across the country and around the world,” spokesman Nick Papas said.

The treatment is called hematopoietic stem cell transplantation (HSCT), consists of removing the patient’s immune and other blood cells, then replacing them with new bone marrow stem cells from the same patient.

But, scientists and doctors not involved with the study recognize that it is a very risky and controversial procedure.

Dr. Aaron Miller, chief medical officer for the National Multiple Sclerosis Society and a professor of neurology at Mount Sinai School of Medicine in New York City, says that the idea behind the procedure is to “reset the thermostat and start fresh,” adding that he does not think the treatment will have a lasting effect on the field.

“This is a very heroic form of therapy for multiple sclerosis [MS], which is unlikely, in my view, ever to have a major impact on the field,” added Miller. “It’s a substantially risky therapy — the mortality rates have been in the 2-3 percent range . . . and it’s hugely expensive.”

The study was started 15 years ago and the results of the study were published in the March 22nd issue of Neurology.

Now, after 15 years, the authors report that overall 25 percent of the 35 initial patients are stabilized. The success rate was better — 44 percent — for those with active brain lesions, signaling aggressive disease, they found.

Many had a lessening of their disability, and fewer and smaller lesions in the brain.

Two participants, or 6 percent, died of complications from the transplant.

The authors of the report say they are continuing their research of the more aggressive types of MS. But, with the high mortality rate of patients in the study, continued research may be difficult because of a lack of volunteers.

Still, some doctors and researchers say that the procedure could be a way to improve the lives of those with aggressive MS, and that it is a good first step in treating aggressive MS.

There are three types of diabetes. Gestational diabetes occurs during pregnancy and will often go away once the pregnancy has been completed. Type 2 diabetes accounts for nearly 90 percent of all diabetics. Type 2 diabetes can be, in most cases, prevented with diet, exercise, oral drugs and even insulin.

Type 1 diabetes is not curable and is only treatable with insulin shots. Type 1 diabetics have to take these shots from the point they are diagnosed for the rest of their life. Diabetes often leads to heart disease, eye problems such as glaucoma, leg and feet problems that can lead to amputations, neuropathy and mental health problems. There is no cure.

But stem cell research has given diabetics hope for a cure after several clinical trials reported success among trial patients. A study done in 2009 reported that diabetics that received new blood stem cells could go without insulin for nearly two and a half years, in the best subjects of the test. Overall, 20 of the 23 patients were able to stay off insulin anywhere from a month to several years. The patients also seemed to have insulin-producing beta cells that are typically destroyed by the auto-immune disease.

Several of the trials have been completed with similar results, and diabetics all over the world are looking forward to stem cell research funding to come through.

Major players profiled in the report include Advanced Cell Technology Inc., Athersys Inc., Cytori Therapeutics Inc., Genzyme Corporation, Geron Corporation, International Stem Cell Corporation, Mesoblast Ltd., Osiris Therapeutics Inc., StemCells Inc., ThermoGenesis Corp., among others.

The research report titled “Stem Cells Research: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the stem cells research markets (including adult stem cells and embryonic stem cells), current market trends, key growth drivers, overview of major types of stem cells, recent product innovations/introductions, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual estimates and forecasts of investments in the area of stem cells research for the years 2006 through 2015 by the following geographic markets – US, Europe, and Rest of World.

Cerebral palsy is a serious disease characterized by brain injury that causes permanent physical disability which cannot be cured. On the other hand, many parents with children suffering from this disease report that they have noticed improvement after their children received a stem cell therapy involving the use of the patients’ own stem cells derived from umbilical cord blood. Clinical trial that will take place at the Duke University and many other research centers worldwide hope to discover enough data to prove that stem cell therapy can help people suffering from cerebral palsy.

The FDA approved clinical trial at the Duke University can be participated only by people who have their umbilical cord blood stored at a bank such as Cryo-Save since birth. In this clinical trial, participants will went through a simple and safe treatment. They will receive a transfusion of their own stem cells from their umbilical cord blood. Then, the researchers will monitor the response of participants to the treatment and hopefully, get enough evidence to support benefits of stem cell therapy for cerebral palsy.

Timothy Ray Brown, also known as the “Berlin Patient,” received the transplant in 2007 as part of a lengthy treatment course for leukemia. His doctors recently published a report in the journal Blood affirming that the results of extensive testing “strongly suggest that cure of HIV infection has been achieved.”

Brown’s case paves a path for constructing a permanent cure for HIV through genetically-engineered stem cells.

Bob Lanza, chief scientific officer at Advanced Cell Technology said that the process has been tested on rats and mice and has been found to halt the progressive disease without causing tumors or other side effects. “These cells have been really performing quite spectacularly in the animals. If we can see that in the human patients we will hit a home run here,” Lanza said.

The trial was allowed to go ahead after the US Food and Drug Administration cleared its application to start a phase I study.